Cancer: Examining the cooperation between extrachromosomal DNA circles
Cells often need to modulate the production of certain proteins to adjust to their ever-changing environment. This is usually achieved by altering the amount of messenger RNAs synthetized from the corresponding genes. Two factors impact the transcription yield of a gene: the number of active copies of this sequence in the genome, and the rate at which each of them is transcribed.
Boosting the production of a protein is usually achieved by increasing transcription rates, but special cases can involve directly creating more copies of the associated gene (Stark and Wahl, 1984). This phenomenon was first identified in amphibian eggs, where it helps cells to produce the elements required for protein synthesis (see Tobler, 1975 for review). In human cells, however, gene amplification is most commonly associated with boosting the expression of cancer-driving genes (Tanaka and Watanabe, 2020). These additional ‘oncogene’ copies can be arranged in tandem in a specific region of a linear chromosome, or they can be contained inside small circles of extrachromosomal DNA (ecDNA) formerly known as double-minute chromosomes (Verhaak et al., 2019; Cox et al., 1965; Figure 1A). A recent study by Hung et al. has reported that oncogenic ecDNAs frequently come together to form hubs of 10 to 100 ecDNA circles; inside these clusters, intermolecular interactions take place that boost oncogene expression (Hung et al., 2021). Now, in eLife, Steven Pollard, Wendy Bickmore and colleagues at the University of Edinburgh — including Karin Purshouse as first author — report new results which contradict these findings (Purshouse et al., 2022).
The team focused on malignant cells from an aggressive type of brain cancer known as glioblastoma; these frequently contain ecDNA circles carrying one or multiple oncogenes. Using super-resolution imaging, Purshouse et al. were able to determine the location of individual ecDNA circles within the nucleus, and how frequently two ecDNAs were found within a given distance. Comparing these numbers with what would be expected if the circles were randomly distributed in the nucleus allowed the team to assess whether ecDNAs form clusters more frequently than anticipated. When analyzing ecDNAs carrying the same oncogene, they found no evidence of clustering of ecDNAs within 200 nm – the distance that corresponds to the estimated diameter of ecDNA hubs.
However, due to the limitation of optical resolution, this approach cannot detect tighter clusters consisting of ecDNAs that are closer than 200nm. To overcome this challenge, Purshouse et al. used another line of glioblastoma cells that carry two distinct types of ecDNAs, which were imaged independently using different probes. This approach makes it possible to spot smaller hubs that bring together different ecDNA ‘species’, yet it also did not provide evidence that ecDNAs cluster in glioblastoma cells.
The team then focused on how ecDNA circles were being transcribed. First, they examined whether oncogenic ecDNAs may be clustering with ‘transcriptional hubs’ that physically bring together various elements of the transcription machinery. However, no spatial correlation was found between ecDNAs and these hubs. Next, they compared how chromosomal and ecDNA copies of the same oncogene were being transcribed. They started by imaging nascent RNA transcripts near individual ecDNA circles, gathering information that allowed them to assess the fraction of ecDNAs that are being actively transcribed at any given time. These analyses captured ‘immature’ RNA transcripts as they were being synthesized, and they showed that ecDNA and chromosomal copies were transcribed at a similar frequency.
Finally, the team switched their focus to mature messenger RNAs. They estimated the fraction of messenger RNAs transcribed from either the ecDNA or the chromosomal copy of an oncogene, using slight differences in the sequences between the two versions. After normalizing for ecDNA and chromosomal copy numbers, they established that an individual sequence, whether chromosomal or extrachromosomal, would produce a similar amount of mature messenger RNAs. Chromosomal DNA and ecDNA therefore appear to be transcribed with a similar efficiency. Taken together, these findings suggest that the transcriptional yield of amplified ecDNAs is primarily determined by the number of ecDNA circles, rather than the cooperative transcription of clustered ecDNAs.
What could explain the discrepancy between these observations and the results reported by Hung et al. (Figure 1B)? Purshouse et al. suggested that both sets of conclusions may in fact be true, but under different circumstances. As these studies relied on a small number of cell lines derived from different types of tumors, diverging results could reflect variations in the size, gene composition or copy number of ecDNAs across cancers. In addition, ecDNAs are highly dynamic; they can recombine, reintegrate within a chromosome or undergo other types of molecular rearrangements which may all alter transcription kinetics (Shoshani et al., 2021; Rosswog et al., 2021). Further studies are now needed to explore the way that ecDNA transcription changes across a wide range of cancers and during disease progression.
References
-
Gene amplificationAnnual Review of Biochemistry 53:447–491.https://doi.org/10.1146/annurev.bi.53.070184.002311
-
BookOccurrence and developmental significance of gene amplificationIn: Weber Rudolf, editors. Biochemistry of Animal Development. New York: Academic Press. pp. 91–143.https://doi.org/10.1016/B978-0-12-740603-9.50009-7
-
Extrachromosomal oncogene amplification in tumour pathogenesis and evolutionNature Reviews. Cancer 19:283–288.https://doi.org/10.1038/s41568-019-0128-6
Article and author information
Author details
Publication history
Copyright
© 2022, Zhang and Zhang
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 659
- views
-
- 67
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Chromosomes and Gene Expression
- Microbiology and Infectious Disease
Candida glabrata can thrive inside macrophages and tolerate high levels of azole antifungals. These innate abilities render infections by this human pathogen a clinical challenge. How C. glabrata reacts inside macrophages and what is the molecular basis of its drug tolerance are not well understood. Here, we mapped genome-wide RNA polymerase II (RNAPII) occupancy in C. glabrata to delineate its transcriptional responses during macrophage infection in high temporal resolution. RNAPII profiles revealed dynamic C. glabrata responses to macrophages with genes of specialized pathways activated chronologically at different times of infection. We identified an uncharacterized transcription factor (CgXbp1) important for the chronological macrophage response, survival in macrophages, and virulence. Genome-wide mapping of CgXbp1 direct targets further revealed its multi-faceted functions, regulating not only virulence-related genes but also genes associated with drug resistance. Finally, we showed that CgXbp1 indeed also affects fluconazole resistance. Overall, this work presents a powerful approach for examining host-pathogen interaction and uncovers a novel transcription factor important for C. glabrata’s survival in macrophages and drug tolerance.
-
- Chromosomes and Gene Expression
- Neuroscience
Pathogenic variants in subunits of RNA polymerase (Pol) III cause a spectrum of Polr3-related neurodegenerative diseases including 4H leukodystrophy. Disease onset occurs from infancy to early adulthood and is associated with a variable range and severity of neurological and non-neurological features. The molecular basis of Polr3-related disease pathogenesis is unknown. We developed a postnatal whole-body mouse model expressing pathogenic Polr3a mutations to examine the molecular mechanisms by which reduced Pol III transcription results primarily in central nervous system phenotypes. Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and exocrine pancreatic atrophy. Transcriptome and immunohistochemistry analyses of cerebra during disease progression show a reduction in most Pol III transcripts, induction of innate immune and integrated stress responses and cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation. Earlier in the disease when integrated stress and innate immune responses are minimally induced, mature tRNA sequencing revealed a global reduction in tRNA levels and an altered tRNA profile but no changes in other Pol III transcripts. Thus, changes in the size and/or composition of the tRNA pool have a causal role in disease initiation. Our findings reveal different tissue- and brain region-specific sensitivities to a defect in Pol III transcription.